| Characteristic | Yamanouchi 2005 |
| I1: pioglitazone C1: metformin C2: glimepiride | |
| Sex [%] | I1: female 53; male 47 C1: female 49; male 51 C2: female 49; male 51 |
| Age [years], mean (SD) | I1: 55 (9) C1: 55 (10) C2: 56 (9) |
| Ethnic groups [%] | ? |
| Duration of disease [years], mean (SD) | I1: 3 (2) C1: 3 (3) C2: 3 (3) |
| Body mass index [kg/m2], mean (SD) | I1: 25.8 (4.2) C1: 26.2 (3.8) C2: 25.6 (3.5) |
| Pharmaco‐naive patients [%] | I1: 100 C1: 100 C2: 100 |
| HbA1c [%], mean (SD) | I1: 10.2 (0.8) C1: 9.9 (0.7) C2: 9.8 (0.7) |
| Co‐morbidities [%] | ? |
| Notes | none |
| Symbols & abbreviations: ? = unclear; I = intervention; C = control SD = standard deviation; SE = standard error | |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.